GSK pulls an­oth­er can­cer in­di­ca­tion for Ze­ju­la at FDA's re­quest

GSK said Fri­day morn­ing that, at the re­quest of the FDA, it will re­strict the sec­ond-line main­te­nance in­di­ca­tion for Ze­ju­la (ni­ra­parib) to on­ly cer­tain can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER